MedTrace Logo

Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)

NCT02080650 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2017-08-01

No results posted yet for this study

Summary

This pilot study will aim to determine whether circulating tumor cells (CTCs) can be captured using the novel cMET based ferrofluid. The primary objective of this pilot study will be to describe the numbers of c-MET expressing cells that can be detected by the c-MET CTC capture technique. These data will be separated by disease site. The investigator will also describe the detection rates of both the c-MET CTC capture and the EpCAM CTC capture techniques in each patient, also separated by disease site.

Conditions

Interventions

DEVICE

Mesenchymal-marker based ferrofluid (c-MET)

DEVICE

Epithelial cell adhesion molecule (EpCAM) ferrofluid

Sponsors & Collaborators

  • Prostate Cancer Foundation

    collaborator OTHER

  • Janssen Diagnostics, LLC

    collaborator INDUSTRY

  • Duke University

    lead OTHER

Principal Investigators

  • Andrew J Armstrong, MD · Duke University

Study Design

Allocation
NON_RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2016-05-19
Completion
2016-07-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02080650 on ClinicalTrials.gov